TY - THES AU - Kovács, Mónika Gabriella TI - Investigation of the pathomechanism and potential therapeutic targets in radiation-induced heart disease in a rat model [A radiogén szívkárosodás pathomechanizmusának és lehetséges terápiás célpontjainak kísérletes vizsgálata patkány modellben] PB - Szegedi Tudományegyetem (SZTE) PY - 2022 SP - 56 DO - 10.14232/phd.11174 UR - https://m2.mtmt.hu/api/publication/32868435 ID - 32868435 LA - English DB - MTMT ER - TY - JOUR AU - Freiwan, Marah AU - Kovács, Mónika Gabriella AU - Kovács, Zsuzsanna AU - Szűcs, Gergő AU - Dinh, Hoa AU - Losonczi, Réka Hajnalka AU - Siska, Andrea AU - Kriston, András AU - Kovács, Ferenc AU - Horváth, Péter AU - Földesi, Imre AU - Cserni, Gábor AU - Dux, László AU - Csont, Tamás Bálint AU - Sárközy, Márta TI - Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 23 PY - 2022 IS - 4 PG - 28 SN - 1661-6596 DO - 10.3390/ijms23042201 UR - https://m2.mtmt.hu/api/publication/32689754 ID - 32689754 N1 - Funding Agency and Grant Number: NKFIHNational Research, Development & Innovation Office (NRDIO) - Hungary [FK129094, GINOP-2.3.2-15-2016-00040]; Stipendium Hungaricum Program; Ministry of Human Capacities [TKP2021-EGA-32]; Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund; Stipendium Hungaricum Scholarship; New National Excellence Program of the Ministry of Human Capacities [UNKP-21-3-SZTE-97, UNKP-21-3-SZTE-98, UNKP-20-5-SZTE-166]; Janos Bolyai Research Fellowship of the Hungarian Academy of SciencesHungarian Academy of Sciences; [EFOP-3.6.3VEKOP-16-2017-00009] Funding text: This research was funded by the projects NKFIH FK129094 (to M.S., funder: National Research, Development and Innovation Office), GINOP-2.3.2-15-2016-00040 (to L.D., funder: National Research, Development and Innovation Office), Stipendium Hungaricum Program (to M.S. and L.D., funder: Tempus Public Foundation), and by the Ministry of Human Capacities TKP2021-EGA-32 (to T.C., Project no. TKP2021-EGA-32 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme.) and by Stipendium Hungaricum Program (to M.S. and L.D., funder: Tempus Public Foundation). M.F. and D.H. were supported by the Stipendium Hungaricum Scholarship (funder: Tempus Public Foundation). M.G.K., Z.Z.A.K., and M.S. were supported by the New National Excellence Program of the Ministry of Human Capacities (UNKP-21-3-SZTE-97 to M.G.K., UNKP-21-3-SZTE-98 to Z.Z.A.K., and UNKP-20-5-SZTE-166 to M.S., funder: Ministry of Human Capacities). M.S. was supported by the Janos Bolyai Research Fellowship of the Hungarian Academy of Sciences. Z.Z.A.K. and M.G.K. were supported by the EFOP-3.6.3VEKOP-16-2017-00009 project (funder: National Research, Development and Innovation Office). The APC was funded by Stipendium Hungaricum Program (funder: Tempus Public Foundation). AB - Despite the effectiveness of doxorubicin (DOXO) as a chemotherapeutic agent, dose-dependent development of chronic cardiotoxicity limits its application. The angiotensin-II receptor blocker losartan is commonly used to treat cardiac remodeling of various etiologies. The beta-3 adrenergic receptor agonist mirabegron was reported to improve chronic heart failure. Here we investigated the effects of losartan, mirabegron and their combination on the development of DOXO-induced chronic cardiotoxicity. Male Wistar rats were divided into five groups: (i) control; (ii) DOXO-only; (iii) losartan-treated DOXO; (iv) mirabegron-treated DOXO; (v) losartan plus mirabegron-treated DOXO groups. The treatments started 5 weeks after DOXO administration. At week 8, echocardiography was performed. At week 9, left ventricles were prepared for histology, qRT-PCR, and Western blot measurements. Losartan improved diastolic but not systolic dysfunction and ameliorated SERCA2a repression in our DOXO-induced cardiotoxicity model. The DOXO-induced overexpression of Il1 and Il6 was markedly decreased by losartan and mirabegron. Mirabegron and the combination treatment improved systolic and diastolic dysfunction and significantly decreased overexpression of Smad2 and Smad3 in our DOXO-induced cardiotoxicity model. Only mirabegron reduced DOXO-induced cardiac fibrosis significantly. Mirabegron and its combination with losartan seem to be promising therapeutic tools against DOXO-induced chronic cardiotoxicity. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Mónika Gabriella AU - Kovács, Zsuzsanna AU - Varga, Zoltán AU - Szűcs, Gergő AU - Freiwan, Marah AU - Farkas, Katalin AU - Kővári, Bence AU - Cserni, Gábor AU - Kriston, András AU - Kovács, Ferenc AU - Horváth, Péter AU - Földesi, Imre AU - Csont, Tamás Bálint AU - Kahán, Zsuzsanna AU - Sárközy, Márta TI - Investigation of the Antihypertrophic and Antifibrotic Effects of Losartan in a Rat Model of Radiation-Induced Heart Disease JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 22 PY - 2021 IS - 23 PG - 24 SN - 1661-6596 DO - 10.3390/ijms222312963 UR - https://m2.mtmt.hu/api/publication/32517976 ID - 32517976 N1 - MEDICS Research Group, Department of Biochemistry, Interdisciplinary Center of Excellence, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, H-6720, Hungary Department of Oncotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, H-6720, Hungary Department of Laboratory Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, H-6720, Hungary Department of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, H-6720, Hungary Synthetic and Systems Biology Unit, Biological Research Centre, Eötvös Loránd Research Network, Szeged, H-6726, Hungary Single-Cell Technologies Ltd, Szeged, H-6726, Hungary Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, 00014, Finland Cited By :1 Export Date: 11 July 2022 Correspondence Address: Csont, T.; MEDICS Research Group, Hungary; email: csont.tamas@med.u-szeged.hu Correspondence Address: Sárközy, M.; MEDICS Research Group, Hungary; email: sarkozy.marta@med.u-szeged.hu LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Zsuzsanna AU - Szűcs, Gergő AU - Freiwan, Marah AU - Kovács, Mónika Gabriella AU - Márványkövi, Fanni AU - Dinh, Hoa AU - Siska, Andrea AU - Farkas, Katalin AU - Kovács, Ferenc AU - Kriston, András AU - Horváth, Péter AU - Kővári, Bence AU - Cserni, Bálint Gábor AU - Cserni, Gábor AU - Földesi, Imre AU - Csont, Tamás Bálint AU - Sárközy, Márta TI - Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 11 PY - 2021 IS - 1 PG - 18 SN - 2045-2322 DO - 10.1038/s41598-021-96815-5 UR - https://m2.mtmt.hu/api/publication/32172362 ID - 32172362 N1 - Funding Agency and Grant Number: NKFIHNational Research, Development & Innovation Office (NRDIO) - Hungary [FK129094, K115990, EFOP-3.6.2-16-2017-00006]; Ministry of Human Capacities [20391-3/2018/FEKUSTRAT]; New National Excellence Program of the Ministry of Human Capacities [UNKP-20-5-SZTE-166, UNKP-19-4SZTE-89, UNKP-19-3-SZTE-160, UNKP-19-3-SZTE-159, UNKP-19-2-SZTE-77]; Janos Bolyai Research Fellowship of the Hungarian Academy of SciencesHungarian Academy of Sciences; Szeged Scientists Academy Program; Ministry of Human Resources [TSZ:34232-3/2016/INTFIN]; [GINOP-2.3.2-15-2016 00040]; [EFOP-3.6.3-VEKOP-16-2017-00009] Funding text: The work and publication were supported by the projects GINOP-2.3.2-15-2016 00040, by the NKFIH FK129094 (to M.S.), NKFIH K115990 (to T.C), EFOP-3.6.2-16-2017-00006 (LIVE LONGER), and by the Ministry of Human Capacities (20391-3/2018/FEKUSTRAT). M.S., Z.Z.A.K., M.G.K., and F.M.M., were supported by the New National Excellence Program of the Ministry of Human Capacities (UNKP-20-5-SZTE-166, UNKP-19-4SZTE-89, UNKP-19-3-SZTE-160, UNKP-19-3-SZTE-159, and UNKP-19-2-SZTE-77). M.S. is supported by the Janos Bolyai Research Fellowship of the Hungarian Academy of Sciences. Z.Z.A.K. and M.G.K. were supported by the EFOP-3.6.3-VEKOP-16-2017-00009 project. FM was supported by the Szeged Scientists Academy Program. The Szeged Scientists Academy Program of the Foundation for the Future of Biomedical Sciences in Szeged is implemented with the support of the Ministry of Human Resources (TSZ:34232-3/2016/INTFIN). LA - English DB - MTMT ER - TY - JOUR AU - Sárközy, Márta AU - Varga, Zoltán AU - Molnár-Gáspár, Renáta AU - Szűcs, Gergő AU - Kovács, Mónika Gabriella AU - Kovács, Zsuzsanna AU - Dux, László AU - Kahán, Zsuzsanna AU - Csont, Tamás Bálint TI - Pathomechanisms and therapeutic opportunities in radiation‑induced heart disease: from bench to bedside JF - CLINICAL RESEARCH IN CARDIOLOGY J2 - CLIN RES CARDIOL VL - 110 PY - 2021 IS - 4 SP - 507 EP - 531 PG - 25 SN - 1861-0684 DO - 10.1007/s00392-021-01809-y UR - https://m2.mtmt.hu/api/publication/31877554 ID - 31877554 N1 - MEDICS Research Group, Department of Biochemistry, Interdisciplinary Center of Excellence, University of Szeged, Szeged, 6720, Hungary Department of Oncotherapy, Faculty of Medicine, University of Szeged, Szeged, 6720, Hungary Department of Biochemistry, Faculty of Medicine, University of Szeged, Szeged, H-6720, Hungary Export Date: 28 May 2021 Correspondence Address: Sárközy, M.; MEDICS Research Group, Hungary; email: sarkozy.marta@med.u-szeged.hu Correspondence Address: Csont, T.; MEDICS Research Group, Hungary; email: csont.tamas@med.u-szeged.hu Correspondence Address: Kahán, Z.; Department of Oncotherapy, Hungary; email: kahan.zsuzsanna@med.u-szeged.hu Chemicals/CAS: alpha tocopherol, 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; amifostine, 20537-88-6; atorvastatin, 134523-00-5, 134523-03-8; captopril, 62571-86-2; colchicine, 64-86-8; enalapril, 75847-73-3; fibroblast growth factor, 62031-54-3; fosinopril, 88889-14-9, 98048-97-6; gelatinase A, 146480-35-5; ibuprofen, 15687-27-1, 79261-49-7, 31121-93-4, 527688-20-6; intercellular adhesion molecule 1, 126547-89-5; interleukin 13, 148157-34-0; interleukin 8, 114308-91-7; interstitial collagenase, 9001-12-1; mevinolin, 75330-75-5; protein kinase B, 148640-14-6; Smad2 protein, 253862-89-4; Smad3 protein, 237417-78-6, 237417-96-8, 237418-00-7; trimetazidine, 13171-25-0, 5011-34-7 Funding details: Hungarian Scientific Research Fund, OTKA Funding details: Magyar Tudományos Akadémia, MTA, EFOP 3.6.3-VEKOP-16-2017-00009 Funding details: Emberi Eroforrások Minisztériuma, EMMI, 20391-3/2018/FEKUSTRAT, UNKP-19-3-SZTE-159, UNKP-19-3-SZTE-160, UNKP-19-4-I-SZTE-89, ÚNKP-20-4-SZTE-150, ÚNKP-20-5-SZTE-166 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH; hu:NKFI, EFOP-3.6.2-16-2017-00006, FK129094 Funding details: Wigner Fizikai Kutatóközpont, Magyar Tudományos Akadémia Funding details: Szegedi Tudományegyetem, SZTE Funding text 1: Open Access funding provided by University of Szeged. The work and publication were supported by the projects GINOP-2.3.2-15-2016-00040, NKFIH FK129094, EFOP-3.6.2-16-2017-00006 (LIVE LONGER) and by the Ministry of Human Capacities (20391-3/2018/FEKUSTRAT). MS, RG, MGK, and ZZAK were supported by the New National Excellence Program of the Ministry of Human Capacities (ÚNKP-20-5-SZTE-166, ÚNKP-20-4-SZTE-150, UNKP-19-4-I-SZTE-89, and UNKP-19-3-SZTE-159, UNKP-19-3-SZTE-160). MS is supported by the János Bolyai Research Fellowship of the Hungarian Academy of Sciences. MGK and ZZAK were supported by the EFOP 3.6.3-VEKOP-16-2017-00009. MEDICS Research Group, Department of Biochemistry, Interdisciplinary Center of Excellence, University of Szeged, Szeged, 6720, Hungary Department of Oncotherapy, Faculty of Medicine, University of Szeged, Szeged, 6720, Hungary Department of Biochemistry, Faculty of Medicine, University of Szeged, Szeged, H-6720, Hungary Export Date: 29 May 2021 Correspondence Address: Sárközy, M.; MEDICS Research Group, Hungary; email: sarkozy.marta@med.u-szeged.hu Correspondence Address: Csont, T.; MEDICS Research Group, Hungary; email: csont.tamas@med.u-szeged.hu Correspondence Address: Kahán, Z.; Department of Oncotherapy, Hungary; email: kahan.zsuzsanna@med.u-szeged.hu Chemicals/CAS: alpha tocopherol, 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; amifostine, 20537-88-6; atorvastatin, 134523-00-5, 134523-03-8; captopril, 62571-86-2; colchicine, 64-86-8; enalapril, 75847-73-3; fibroblast growth factor, 62031-54-3; fosinopril, 88889-14-9, 98048-97-6; gelatinase A, 146480-35-5; ibuprofen, 15687-27-1, 79261-49-7, 31121-93-4, 527688-20-6; intercellular adhesion molecule 1, 126547-89-5; interleukin 13, 148157-34-0; interleukin 8, 114308-91-7; interstitial collagenase, 9001-12-1; mevinolin, 75330-75-5; protein kinase B, 148640-14-6; Smad2 protein, 253862-89-4; Smad3 protein, 237417-78-6, 237417-96-8, 237418-00-7; trimetazidine, 13171-25-0, 5011-34-7 Funding details: Hungarian Scientific Research Fund, OTKA Funding details: Magyar Tudományos Akadémia, MTA, EFOP 3.6.3-VEKOP-16-2017-00009 Funding details: Emberi Eroforrások Minisztériuma, EMMI, 20391-3/2018/FEKUSTRAT, UNKP-19-3-SZTE-159, UNKP-19-3-SZTE-160, UNKP-19-4-I-SZTE-89, ÚNKP-20-4-SZTE-150, ÚNKP-20-5-SZTE-166 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH; hu:NKFI, EFOP-3.6.2-16-2017-00006, FK129094 Funding details: Wigner Fizikai Kutatóközpont, Magyar Tudományos Akadémia Funding details: Szegedi Tudományegyetem, SZTE Funding text 1: Open Access funding provided by University of Szeged. The work and publication were supported by the projects GINOP-2.3.2-15-2016-00040, NKFIH FK129094, EFOP-3.6.2-16-2017-00006 (LIVE LONGER) and by the Ministry of Human Capacities (20391-3/2018/FEKUSTRAT). MS, RG, MGK, and ZZAK were supported by the New National Excellence Program of the Ministry of Human Capacities (ÚNKP-20-5-SZTE-166, ÚNKP-20-4-SZTE-150, UNKP-19-4-I-SZTE-89, and UNKP-19-3-SZTE-159, UNKP-19-3-SZTE-160). MS is supported by the János Bolyai Research Fellowship of the Hungarian Academy of Sciences. MGK and ZZAK were supported by the EFOP 3.6.3-VEKOP-16-2017-00009. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Mónika Gabriella AU - Kiscsatári, Laura AU - Varga, Zoltán AU - Kővári, Bence AU - Fábián, Gabriella AU - Cserni, Gábor AU - Thum, Thomas AU - Csont, Tamás Bálint AU - Bátkai, Sándor AU - Barnea, Eytan AU - Kahán, Zsuzsanna AU - Sárközy, Márta TI - The effect of the preimplantation factor on the cardiac expression of miR-21 in radiation-induced heart disease JF - ACTA PHYSIOLOGICA J2 - ACTA PHYSIOL VL - 227 PY - 2019 IS - Special Issue S718 SP - 166 EP - 167 PG - 2 SN - 1748-1708 UR - https://m2.mtmt.hu/api/publication/31290812 ID - 31290812 N1 - GINOP-2.3.2-15-2016-00040, FK129094,UNKP-19-3-SZTE-159, UNKP-19-4-SZTE-89), János Bolyai Research Fellowship of the Hungarian Academy of Sciences, EFOP-3.6.3-VEKOP-16-2017-00009 LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Mónika Gabriella AU - Kiscsatári, Laura AU - Varga, Zoltán AU - Kővári, Bence AU - Fábián, Gabriella AU - Cserni, Gábor AU - Thomas, Thum AU - Csont, Tamás Bálint AU - Bátkai, Sándor AU - Eytan, Barnea AU - Kahán, Zsuzsanna AU - Sárközy, Márta TI - A preimplantációs faktor hatása a miR-21 kardiális expressziójára radiogén szívkárosodásban [The effect of preimplantation factor on the cardiac expression of miR-21 in radiation-induced heart disease] JF - CARDIOLOGIA HUNGARICA J2 - CARDIOL HUNG VL - 49 PY - 2019 IS - Supplementum B SP - B29 EP - B30 PG - 1 SN - 0133-5596 UR - https://m2.mtmt.hu/api/publication/31290227 ID - 31290227 N1 - ÚNKP- 17-4-I-SZTE-43, ÚNKP-17-2-I-SZTE-30, ÚNKP-18-4-SZTE-63, ÚNKP-18-3-II-SZTE-15, GINOP-2.3.2-15-2016-00040, NKFIH_FK129094 LA - English DB - MTMT ER - TY - GEN AU - Kovács, Zsuzsanna AU - Kovács, Mónika Gabriella AU - Szűcs, Gergő AU - Andrea, Siska AU - Imre, Földesi AU - Csont, Tamás Bálint AU - Sárközy, Márta TI - The anti-hypertrophic effect of the beta-3 adrenergic receptor agonist mirabegron in experimental uremic cardiomyopathy PY - 2019 UR - https://m2.mtmt.hu/api/publication/31289430 ID - 31289430 N1 - GINOP-2.3.2-15-2016-00040,, ÚNKP-19-3-SZTE-160, ÚNKP-19-3-SZTE-159, ÚNKP-19-4-SZTE-89, NKFIH K115990, NKFIH FK129094, EFOP-3.6.3-VEKOP-16-2017-00009 LA - English DB - MTMT ER - TY - GEN AU - Kovács, Mónika Gabriella AU - Kovács, Zsuzsanna AU - Varga, Zoltán AU - Fábián, Gabriella AU - Eytan, Barnea AU - Kahán, Zsuzsanna AU - Csont, Tamás Bálint AU - Sárközy, Márta TI - The potential anti-hypertrophic effect of the preimplantation factor in the development of radiation-induced heart disease in rats PY - 2019 PG - 1 UR - https://m2.mtmt.hu/api/publication/31289423 ID - 31289423 N1 - GINOP-2.3.2-15-2016-00040, NKFIH_FK129094,NKFIH K115990,EFOP 3.6.3-VEKOP-16-2007-00002,EFOP-3.6.2-16-2017-00006,ÚNKP-19-3-SZTE-160, ÚNKP-19-3-159, ÚNKP-19-4-SZTE-89 LA - English DB - MTMT ER - TY - CHAP AU - Sárközy, Márta AU - Molnár-Gáspár, Renáta AU - Zvara, Ágnes AU - Siska, Andrea AU - Kővári, Bence AU - Szűcs, Gergő AU - Márványkövi, Fanni AU - Kovács, Mónika Gabriella AU - Diószegi, Petra AU - Bodai, László AU - Zsindely, Nóra AU - Pipicz, Márton AU - Gömöri, Kamilla AU - Kiss, Krisztina AU - Bencsik, Péter AU - Cserni, Gábor AU - Puskás, László AU - Földesi, Imre AU - Thum, Thomas AU - Bátkai, Sándor AU - Csont, Tamás Bálint ED - Bagdy, György TI - Krónikus veseelégtelenségben megemelkedik a prohipertrófiás miR-212 bal kamrai expressziója T2 - FAMÉ 2019 Magyar Kísérletes és Klinikai Farmakológiai Társaság; Magyar Anatómus Társaság; Magyar Mikrocirkulációs és Vaszkuláris Biológiai Társaság; Magyar Élettani Társaság PB - Expert-Quality Kongresszusi és Utazási Iroda CY - Budapest SN - 9786158129909 PY - 2019 SP - 107 EP - 108 PG - 2 UR - https://m2.mtmt.hu/api/publication/31289422 ID - 31289422 N1 - Új Nemzeti Kiválóság Program (UNKP-17-2-I-SZTE-9, UNKP-17-4-I-SZTE-43, UNKP-18-4-63) NKFIH K115990,GINOP-2.3.2-15-2016-00040, Szegedi Tudós Akadémia program (EMMI, TSZ:34232-3/2016/INTFIN) LA - Hungarian DB - MTMT ER -